Hye Ryeon Kim Hyunji Jo Hongsik Kim Joohyun Hong Sehhoon Park Hyun Ae Jung Se-Hoon Lee Jin-Seok Ahn Myung-Ju Ahn
10.4143/crt.2021.1603
Cancer Res Treat
2023 Jan;55(1):344-349.
egfr mutant nsclc leptomeningeal metastasis osimertinib systemic chemotherapy
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/35344648/
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics Meningeal Carcinomatosis / drug therapy Meningeal Carcinomatosis / genetics Meningeal Carcinomatosis / secondary
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics Meningeal Carcinomatosis / drug therapy Meningeal Carcinomatosis / genetics Meningeal Carcinomatosis / secondary Case Reports ErbB Receptors Humans Mutation Prospective Studies Protein Kinase Inhibitors / adverse effects osimertinib ErbB Receptors Protein Kinase Inhibitors EGFR protein, human
PMC9873340
35344648
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
2023